A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

Keyphrases

• Cancer Types 100%
• Patient Samples 100%
• Pan-cancer Analysis 100%
• Enhancer Activity 66%
• Tumor 33%
• Tumor Samples 33%
• Co-expression 33%
• In Cancer 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Non-coding 33%
• Cancer Development 33%
• Aneuploidy 33%
• Computational Methods 33%
• RNA-seq Data 33%
• Chromatin State 33%
• Genome-wide Analysis 33%
• Expression Quantitative Trait Loci (eQTL) 33%
• Gene Relationship 33%
• Mutation Load 33%
• Gene-gene Interaction 33%
• Immunotherapy Targets 33%
• Actionable Genes 33%
• Enhancer Activation 33%
• Regulatory DNA Elements 33%
• Hi-C Data Analysis 33%

Biochemistry, Genetics and Molecular Biology

• Enhancer Region 100%
• Pan-cancer 100%
• Genome Wide Association Study 9%
• RNA Sequencing 9%
• Aneuploidy 9%
• Gene Interaction 9%
• PD-L1 9%
• Expression Quantitative Trait Loci 9%
• Mutational Load 9%
• Messenger RNA 9%